|Bid||0.00 x 800|
|Ask||6.80 x 1300|
|Day's Range||6.12 - 6.46|
|52 Week Range||2.78 - 9.02|
|Beta (3Y Monthly)||-0.52|
|PE Ratio (TTM)||N/A|
|Earnings Date||Aug 7, 2017 - Aug 11, 2017|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||12.33|
Quotient (QTNT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
JERSEY, Channel Islands, Oct. 22, 2018 -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company, today announced that financial results for its fiscal second.
JERSEY, Channel Islands, Sept. 26, 2018-- Quotient, a commercial-stage diagnostics company, today announced that the Company's Chairman and Chief Executive Officer, Franz Walt, will present at the 2018 ...
“We are happy to report the successful on time submission of the CE mark filing for our initial IH microarray. Final examination of the underlying data has shown further improvement from the field trial results we previously shared.
Quotient (QTNT) delivered earnings and revenue surprises of -48.65% and 14.25%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
On a per-share basis, the Eysins, Jersey-based company said it had a loss of 55 cents. The blood test developer posted revenue of $7.9 million in the period. Quotient shares have risen 55 percent since ...
$48.8 million of proceeds from warrant exercises received through July 31 $36 million of additional senior notes issued and funded in June Initial SDS microarray verification and validation started Record ...
Stock Research Monitor: QTNT, ADMP, and PETS LONDON, UK / ACCESSWIRE / June 28, 2018 / If you want a free Stock Review on VRX sign up now at www.wallstequities.com/registration . On Wednesday, June 27, ...
Quotient Limited’s (NASDAQ:QTNT): Quotient Limited, a commercial-stage diagnostics company, develops, manufactures, and commercializes conventional reagent products used for blood grouping in the transfusion diagnostics market worldwide. The US$402.65m market-cap companyRead More...
On a per-share basis, the Eysins, Jersey-based company said it had a loss of 44 cents. The blood test developer posted revenue of $6.1 million in the period. For the year, the company reported that its ...
Understanding how Quotient Limited (NASDAQ:QTNT) is performing as a company requires looking at more than just a years’ earnings. Today I will run you through a basic sense check toRead More...